论文部分内容阅读
目的探讨术前放疗联合术后XELOX方案新辅助化疗治疗Ⅲ期进展期胃癌的临床疗效。方法选取平顶山市第一人民医院2013年1月至2014年1月收治的94例Ⅲ期进展期患者随机分为两组,每组47例。两组均给予手术及术后XELOX方案新辅助化疗,而观察组加用术前放疗,3周为1个疗程。化疗4个疗程。比较两组手术切除率、手术死亡率、并发症发生率及术后生存率。结果观察组肿瘤切除率、肿瘤根治性切除率及术后3年生存率分别为93.6%、70.2%、61.7%,均明显高于对照组的77.3%、46.8%、38.3%,差异有统计学意义(P<0.05);观察组手术病死率及并发症发生率分别为2.1%、17.0%,与对照组的4.2%、14.9%相近,差异无统计学意义(P>0.05)。结论术前放疗联合术后XELOX方案新辅助化疗治疗Ⅲ期进展期胃癌,有助于提高肿瘤切除率,减少复发率,提高远期生存率。
Objective To investigate the clinical efficacy of preoperative radiotherapy combined with postoperative XELOX regimen neoadjuvant chemotherapy in the treatment of stage Ⅲ advanced gastric cancer. Methods Ninety-four patients with stage Ⅲ advanced from January 2013 to January 2014 in Pingdingshan First People’s Hospital were randomly divided into two groups with 47 cases in each group. Both groups were given neoadjuvant chemotherapy for surgery and postoperative XELOX regimen, while the observation group received preoperative radiotherapy for 3 weeks as a course of treatment. Chemotherapy 4 courses. Surgical resection rate, operative mortality rate, complication rate and postoperative survival rate were compared between the two groups. Results The tumor resection rate, radical resection rate and 3-year survival rate were 93.6%, 70.2% and 61.7% in the observation group, which were significantly higher than those in the control group (77.3%, 46.8% and 38.3%, respectively) (P <0.05). The mortality rate and complication rate in the observation group were 2.1% and 17.0% respectively, which were similar to those in the control group (4.2% and 14.9%, respectively). There was no significant difference between the two groups (P> 0.05). Conclusions Preoperative radiotherapy combined with postoperative XELOX regimen neoadjuvant chemotherapy for advanced stage Ⅲ gastric cancer can help improve tumor resection rate, reduce recurrence rate and improve long-term survival rate.